Volume 383, Issue 9918, Pages 697-704 (February 2014) Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial  Prof D Nicholas Bateman, MD, James W Dear, PhD, H K Ruben Thanacoody, MD, Simon H L Thomas, MD, Michael Eddleston, PhD, Euan A Sandilands, MB, Judy Coyle, BSc, Jamie G Cooper, MB, Aryelly Rodriguez, MSc, Isabella Butcher, PhD, Steff C Lewis, PhD, A D Bastiaan Vliegenthart, BSc, Aravindan Veiraiah, MB, Prof David J Webb, DSc, Alasdair Gray, MD  The Lancet  Volume 383, Issue 9918, Pages 697-704 (February 2014) DOI: 10.1016/S0140-6736(13)62062-0 Copyright © 2014 Bateman et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 1 Trial profile One patient had incomplete data at 2 h but completed the trial. *Other reasons for exclusion: unlikely to complete treatment (n=27), life-threatening illness (17), detained under the Mental Health Act (15), permanent cognitive impairment (9), pregnant (6), on anticoagulants (5); non-English speaking (4), unable to complete questionnaires (3), and history of hypersensitivity to serotonin antagonists (3). The Lancet 2014 383, 697-704DOI: (10.1016/S0140-6736(13)62062-0) Copyright © 2014 Bateman et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 2 Kaplan-Meier plot of patients who did not need antiemetic rescue for 0–12 h, by treatment regimen The Lancet 2014 383, 697-704DOI: (10.1016/S0140-6736(13)62062-0) Copyright © 2014 Bateman et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 3 Kaplan-Meier plot of patients who did not need treatment for anaphylactoid reactions for 0–12 h, by treatment regimen The Lancet 2014 383, 697-704DOI: (10.1016/S0140-6736(13)62062-0) Copyright © 2014 Bateman et al. Open Access article distributed under the terms of CC BY Terms and Conditions